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Staphylococcus aureus Hijacks a Skin Commensal
to Intensify Its Virulence: Immunization Targeting
b-Hemolysin and CAMP Factor
Chih-Wei Lo1,2,3, Yiu-Kay Lai3, Yu-Tsueng Liu4,5, Richard L. Gallo1,2 and Chun-Ming Huang1,2,5
The need for a new anti-Staphylococcus aureus therapy that can effectively cripple bacterial infection,
neutralize secretory virulence factors, and lower the risk of creating bacterial resistance is undisputed. Here, we
propose what is, to our knowledge, a previously unreported infectious mechanism by which S. aureus may
commandeer Propionibacterium acnes, a key member of the human skin microbiome, to spread its invasion
and highlight two secretory virulence factors (S. aureus b-hemolysin and P. acnes CAMP (Christie, Atkins,
Munch-Peterson) factor) as potential molecular targets for immunotherapy against S. aureus infection. Our
data demonstrate that the hemolysis and cytolysis by S. aureus were noticeably augmented when S. aureus
was grown with P. acnes. The augmentation was significantly abrogated when the P. acnes CAMP factor was
neutralized or b-hemolysin of S. aureus was mutated. In addition, the hemolysis and cytolysis of recombinant
b-hemolysin were markedly enhanced by recombinant CAMP factor. Furthermore, P. acnes exacerbated
S. aureus-induced skin lesions in vivo. The combination of CAMP factor neutralization and b-hemolysin immunization
cooperatively suppressed the skin lesions caused by coinfection of P. acnes and S. aureus. These observations suggest
a previously unreported immunotherapy targeting the interaction of S. aureus with a skin commensal.
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INTRODUCTION
Staphylococcus aureus, a Gram-positive bacterium, is a
major causes of fatal nosocomial infections (Homa and
Palfreyman, 2000). It is estimated that S. aureus accounts for
12 million outpatient visits and 292,000 hospitalizations
annually in the United States alone, of which 126,000 are
due to methicillin-resistant S. aureus (MRSA) (Goetghebeur
et al., 2007). Recent studies estimated that more people
die from MRSA bacterium than from HIV in the United
States (Klevens et al., 2008; Payne, 2008). In addition, MRSA
infections have recently been found in increasing numbers
among individuals in the community without health-care
exposure (Wilson and Rinker, 2009). Although S. aureus,
including MRSA and community-associated MRSA, can
cause life-threatening and systemic infection, skin and soft
tissue are the most common sites of S. aureus infection,
comprising 475% of MRSA disease (Cohen et al., 2007).
Nearly everyone hosts Propionibacterium acnes (Brook and
Frazier, 1991; Ahn et al., 1996), which accounts for
approximately half of the total skin microbiome (Tancrede,
1992), with an estimated density of 102–105–6 cm2 (McGinley
et al., 1978; Leyden et al., 1998). P. acnes predominates
(460% of total bacteria) in facial skin (Grice et al., 2009);
however, it can be found almost everywhere on the body
(Yamada et al., 2002; Nishiwaki et al., 2004). There is growing
evidence that P. acnes and S. aureus coexist in many human
diseases, including acne lesions (Williams et al., 1992), implant
infections (Ramage et al., 2003; Bashir et al., 2007), and sepsis
(Duncan and Sperling, 2008). This indicates that the patho-
genic S. aureus may interact with residential P. acnes during
infection in humans, and it might therefore be important to
understand the role of P. acnes in S. aureus infection.
Developing effective therapeutic approaches for S. aureus
or MRSA treatment remains an unmet challenge because
of its formidable resistance against multiple traditional
antibiotics such as methicillin, cloxacillin, and flucloxacillin
(Takizawa et al., 2005; Takano et al., 2007). Current
antibiotic therapy nonspecifically eliminates the majority of
bacteria, which impacts human microbiome homeostasis
(Jeong et al., 2009) and increases the risk of developing
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resistant bacteria. Past efforts to generate vaccines against
S. aureus have been unsuccessful. Anti–S. aureus vaccines
targeting surface proteins (e.g., clumping factor) have failed
in clinical trials (Shinefield and Black, 2005; DeJonge et al.,
2007). Other anti–S. aureus vaccines targeting surface mole-
cules (e.g., poly-N-succinyl b-1–6-glucosamine (McKenney
et al., 1999) and iron-regulated surface determinants A, B, D,
and E (Stranger-Jones et al., 2006)) have subsequently
been developed. A recent vaccine using a secretory toxin
(a-hemolysin) as an antigen (Bubeck Wardenburg and
Schneewind, 2008) emphasizes the notion that targeting
secretory virulence factors rather than bacterial surface
proteins creates a more effective therapy with a lower
tendency to select for resistance. Although these vaccines
had been demonstrated to be effective in mice, none of them
was constructed taking into account the interaction of
S. aureus with human commensal bacteria. Without this
consideration, the efficacy of these vaccines becomes
doubtful when they are translated from mice to humans.
Here, we have demonstrated that the secretory
CAMP (Christie, Atkins, Munch-Peterson) factor of P. acnes
enhances hemolysis and cytolysis by S. aureus b-hemolysin,
suggesting that S. aureus may shrewdly utilize the secreted
P. acnes CAMP factor to intensify its virulence. The results
revealed an intriguing interaction of S. aureus with human
commensals at the initial stage of infection and two potential
therapeutic targets (P. acnes CAMP factor and S. aureus
b-hemolysin) for treatment of S. aureus infection.
RESULTS
P. acnes amplified the hemolytic activity of S. aureus
When S. aureus (S. aureus 113) was grown with P. acnes
(ATCC 6919) on a sheep blood agar plate, we found that the
hemolytic activity of S. aureus was dramatically augmented in
comparison with that of S. aureus or P. acnes alone (Figure 1a).
Accordingly, the colony-forming units (CFUs) of S. aureus in
culture alone or in a coculture of S. aureus and P. acnes were
not distinct (Supplementary Figure S1 online), suggesting that
P. acnes did not influence the growth of S. aureus. However,
this augmentation of hemolysis did not appear when S. aureus
113 was cocultured with Staphylococcus epidermidis (ATCC
12228), one of the human skin commensal bacteria (Figure 1b;
Otto, 2009), which indicated that hemolytic augmentation of
S. aureus was specifically mediated by P. acnes and was not a
result of an increase in the growth of S. aureus.
P. acnes CAMP factor is involved in the hemolysis and cytolysis
of S. aureus
It has been reported that the CAMP factors of Streptococcus
agalactiae (Schneewind et al., 1988), Streptococcus uberis
(Jiang et al., 1996), and Streptococcus pyogenes (Gase et al.,
1999) exhibit the CAMP reactions that can enhance the
hemolytic activity of S. aureus. Spotting P. acnes CAMP factor
(accession number AY726656), but not a control green
fluorescence protein (GFP), considerably increased the inten-
sity of the diffusion zone of the hemolysis of S. aureus
(Figure 2a), supporting the notion that the P. acnes CAMP
factor with a CAMP reaction exerts cohemolytic activity. It has
been known that macrophages are essential for the initiation
and execution of inflammatory response and subsequent
resolution of bacterial infection (Kobayashi et al., 2006).
We exposed murine RAW264.7 macrophage cells to culture
supernatants of bacteria and found that secretory components
from P. acnes and S. aureus cooperatively enhance the
cytolysis of S. aureus (Figure 2b). In addition, neutralization
of P. acnes CAMP factor markedly suppressed the cytotoxicity
of macrophages induced by the supernatants of bacterial
coculture (Figure 2b), indicating that CAMP factor was
involved in the enhancement of cytolysis of S. aureus. The
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Figure 1. Propionibacterium acnes, not Staphylococcus epidermidis,
enhances the hemolytic activity of Staphylococcus aureus. (a) P. acnes alone
(PA, 2 107 colony-forming units (CFUs)), S. aureus 113 alone (SA,
2 107CFUs), P. acnes plus S. aureus (PAþ SA, 1:1 ratio with a total of
2 107CFUs), (b) S. epidermidis alone (SE, 2 107CFUs), or S. epidermidis
plus S. aureus (SEþ SA, 1:1 ratio with a total of 2 107CFUs) were suspended
in 10 ml PBS and streaked on sheep blood agar plates at 371C for 2 days under
anaerobic conditions. Hemolytic activity was determined as described in
Materials and Methods. Bar¼1 cm. Data are representative of three separate
experiments with similar results.
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antisera were obtained from mice as described in Materials
and Methods. The specificity of antiserum against CAMP factor
was verified by western blotting (shown in the inset panel in
Figure 2b).
Induction of proinflammatory cytokines also has a crucial
role in the progression of bacterial infection. We next exam-
ined whether P. acnes alters the levels of S. aureus–induced
proinflammatory cytokines in vivo. Ears of imprinting control
region (ICR) mice were intradermally injected with bacteria
for 24 hours and subsequently excised to homogenize for
detection of macrophage inflammatory protein-2 (MIP-2)
levels in the supernatants. As shown in Figure 2c, coinjection
of P. acnes and S. aureus significantly elevated the level
of MIP-2 (11.87±1.72 ngml1) compared with the injection
of P. acnes (2.58±0.94 ngml1) or S. aureus (8.78±1.23
ngml1) alone. Subsequently, the neutralization of P. acnes
with anti-CAMP factor (5.76±1.48 ngml1), but not anti-GFP
(14.61±3.36 ngml1), antiserum notably reduced the level
of MIP-2 induced by bacterial coinjection. The data in
Figure 2 indicate that P. acnes CAMP factor exhibited
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Figure 2. Propionibacterium acnes Christie, Atkins, Munch-Peterson (CAMP) factor mediates the enhancement of hemolysis and cytolysis caused by a
coculture of P. acnes with Staphylococcus aureus. (a) A total of 10 mg of recombinant CAMP factor and green fluorescence protein (GFP) in 5 ml phosphate-
buffered saline (PBS) was spotted (circles) adjacent to a S. aureus 113 (1 105 colony-forming units (CFUs) in 10ml PBS) streak on a sheep blood agar plate
grown overnight at 371C. Bar¼ 1 cm. (b) Macrophage RAW264.7 cells were treated with PBS or bacterial culture supernatants (10 mgml1) of P. acnes (PA),
S. aureus (SA), or P. acnes plus S. aureus (PAþ SA). Bacterial culture supernatants of coculture of P. acnes and S. aureus were incubated with 5% (v/v) anti-CAMP
factor or anti-GFP (as a negative control) antiserum. The in vitro cytotoxicity assay was performed after cells were treated with the mixture of bacterial culture
supernatant and antiserum for 24 hours. Western blot analysis was conducted to validate the specificity of anti-CAMP factor antiserum (arrowhead in the inset
panel). One microgram of recombinant CAMP factor was separated via 12% SDS-PAGE, transferred to an Immobilon-P polyvinylidene difluoride membrane,
and reacted with anti-CAMP factor (right lane) or anti-GFP antiserum (left lane), in 1:2,000 dilution. (c) Neutralization of CAMP factor significantly diminishes
the enhancement of P. acnes on the S. aureus-induced macrophage inflammatory protein-2 (MIP-2) production. PBS (25ml), P. acnes (PA, 25ml; 2107CFUs),
S. aureus 113 (SA, 25ml; 2 107CFUs), or a mixture of P. acnes plus S. aureus 113 (PAþ SA, 25ml; 1:1 ratio with a total of 2 107CFUs) was intradermally
injected into the ears of imprinting control region (ICR) mice. The mixture of P. acnes and S. aureus (PAþ SA) was preincubated with 5% (v/v) anti-CAMP factor
or anti-GFP antiserum at 251C for 1 hour to neutralize the P. acnes CAMP factor. After incubation, the bacteria alone or bacteria preincubated with antiserum
were intradermally injected into ears of ICR mice. After injection for 24 hours, ears were excised, homogenized, and centrifuged. ELISA was performed to
measure the proinflammatory MIP-2 cytokine in supernatant. The data are represented as mean±SE (n¼ 3, *Po0.05 and **Po0.005 by Student’s t-test).
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cohemolytic activity and was an indispensable secretory
protein in P. acnes that enhanced the virulence of S. aureus.
S. aureus b-hemolysin is associated with CAMP factor in the
enhancement of hemolysis and cytolysis
It has been documented that P. acnes CAMP factor can
potentiate the hemolytic activity of S. aureus b-hemolysin, a
secretory virulence factor (Huseby et al., 2007). Spotting
recombinant CAMP factor with recombinant b-hemolysin, but
not with recombinant a-hemolysin, on a sheep blood agar
plate for 1 day showed synergistic enhancement of hemolysis
(Figure 3a). The hemolysis assay showed that incubation of
erythrocytes with wild-type S. aureus and P. acnes displayed
greater hemolytic activity than incubation with individual
S. aureus or P. acnes (Figure 3b). The enhancement of
hemolytic activity was completely abrogated when P. acnes
was coincubated with b-hemolysin-deficient (SAhlb) strains
(Figure 3b), but not with a-hemolysin (SAhla) strains (Supple-
mentary Figure S2 online). To further investigate whether
b-hemolysin strengthened the cytolysis of CAMP factor,
RAW264.7 cells were treated with 200mgml1 of recombi-
nant GFP, CAMP factor, b-hemolysin, or a mixture of
b-hemolysin plus CAMP factor or GFP for 18hours (Figure
3c). As expected, the cytolysis of b-hemolysin (37.92±2.4%)
was strikingly reinforced when cells were treated with the
mixture of b-hemolysin and CAMP factor (81.09±5.45%).
P. acnes exacerbates S. aureus–induced skin lesions
To gain insight into the interaction of S. aureus and P. acnes
in vivo, skin lesions were made by injection of bacteria into
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Figure 3. Staphylococcus aureus b-hemolysin contributes to the augmentation of hemolysis and cytolysis caused by coculture of Propionibacterium acnes
and S. aureus. (a) Recombinant b-hemolysin (5 mg; Toxin Technology, Sarasota, FL), Christie, Atkins, Munch-Peterson (CAMP) factor (5 mg), and a-hemolysin
(1 mg) in 5 ml phosphate-buffered saline (PBS) were spotted on sheep blood agar plates to examine the hemolytic activity. Recombinant green fluorescence
protein (GFP; 5 mg) in 5 ml PBS was used as a control. (b) P. acnes (PA, 2 107 colony-forming units (CFUs)) alone, wild-type S. aureus alone (SAwt,
2 107CFUs), or P. acnes plus wild-type S. aureus (1:1 ratio with a total of 2 107CFUs) was incubated with sheep blood cells at 371C with end-over-end
rotation for 2 days. Hemolytic activity was detected by measuring the absorbance of hemoglobin release at 540 nm. To examine the essentiality of S. aureus
b-hemolysin in the enhancement of hemolysis by coculture of P. acnes and S. aureus, a b-hemolysin-deficient S. aureus (SAhlb, 2 107CFUs) was incubated
with sheep blood cells (PAþ SAhlb in 1:1 ratio with a total of 2 107CFUs) in the absence and presence of P. acnes. . (c) To determine the synergistic effect
of CAMP factor and b-hemolysin on cytotoxicity, macrophage RAW264.7 cells (1105 per well) were incubated with 10 ml of 200mgml1 recombinant
proteins of GFP, CAMP factor, b-hemolysin, or the mixture of b-hemolysin plus CAMP factor or GFP at 371C for 18 hours. An equal volume of PBS was used as a
negative control. After incubation, the cytotoxicity of recombinant proteins to macrophages was determined by an in vitro cytotoxicity assay as described in
Materials and Methods. Data are represented as mean±SE (n¼ 3, **Po0.005 by Student’s t-test). NS, not significant.
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the dorsal skin of ICR mice, a mouse strain with diversity in
gene function that more closely resembles the human
population. Injection of wild-type S. aureus (National Collec-
tion of Type Cultures (8325-4; 11.11±3.96mm2), but not
P. acnes, for 2 days induced the development of skin lesions
(Figure 4) that recapitulate an ulcerative response of S. aureus
infection in humans. The lesions (29.01±4.75mm2) were
significantly exacerbated when mice were coinjected with
S. aureus and P. acnes.
S. aureus b-hemolysin is immunogenic
To explore the value of a therapy targeting b-hemolysin, we
first examined the antigenicity of b-hemolysin. An expressed
protein matching b-hemolysin with a molecular weight of
B33 kDa was detected by SDS-PAGE after isopropyl-b-D-
thiogalactopyranoside induction (Figure 5a left panel) and
protein purification (Figure 5a right panel). It was further
validated via sequencing by Nano liquid chromatography
linear trap quadrupole tandem mass spectrometry (West
Palm Beach, FL) after in-gel trypsin digestion (Figure 5b).
Twenty-seven peptides were fully sequenced and matched
well with internal amino acids of S. aureus b-hemolysin
(Supplementary Table S1 online). A sequenced peptide
(NNDVVIFNEAFDNGASDK; 78–95 amino acid residues)
of b-hemolysin is presented in Figure 5b. To examine the
immunogenicity of b-hemolysin, we immunized ICR mice
intranasally with UV-inactivated E. coli overexpressing
b-hemolysin or GFP (a control protein). Immunization of
UV-inactivated E. coli overexpressing antigens has been
demonstrated in our previous efforts (Liu et al., 2008).
A single band was detected in western blot analysis when
recombinant b-hemolysin was immunoreacted with serum
obtained from immunized mice, indicating that b-hemolysin
was immunogenic (Figure 5c).
The combination of b-hemolysin immunization with passive
neutralization of CAMP factor confers protection against skin
lesions
To assess the effect of immunization with UV-inactivated
E. coli overexpressing b-hemolysin and/or neutralization of
CAMP factor on the bacteria-induced skin lesions, immuni-
zed mice were injected subcutaneously with both S. aureus
and P. acnes in the presence of antiserum against CAMP
factor or GFP. In GFP-immunized mice, a massive lesion size
(30.01±12.96mm2) developed after injection with bacteria
in the presence of antiserum against GFP. However, the
lesion (7.91±2.67mm2) was significantly decreased in
b-hemolysin-immunized mice (Figure 5d). Similarly, the
lesion (9.53±3.83mm2) was markedly attenuated in GFP-
immunized mice accompanied by passive neutralization of
antiserum against CAMP factor (Figure 5d and e). The results
indicated that immunization targeting either S. aureus
b-hemolysin or P. acnes CAMP factor can effectively protect
mice from skin lesions caused by coinfection of S. aureus and
P. acnes. To exclude the possibility of anti-CAMP factor
antibody crossreacting with S. aureus directly, the S. aureus
bacteria treated with and without anti-CAMP factor antiserum
were subcutaneously injected into the dorsal skin of ICR mice
to induce skin lesions. As shown in Supplementary Figure S3
online, there is no difference in the size of lesions caused by
S. aureus treated with or without anti-CAMP factor antiserum,
suggesting that anti-CAMP factor antiserum did not affect the
S. aureus-induced skin lesions.
To investigate whether abrogation of both b-hemolysin and
CAMP factor provided greater protection, mice immunized to
b-hemolysin accompanied by passive neutralization of antiser-
um against CAMP factor were coinjected with S. aureus and
P. acnes. The bacteria-induced lesion size (3.46±1.17mm2)
was considerably reduced only in the case of both S. aureus
b-hemolysin immunization and P. acnes CAMP factor neutra-
lization (Figure 5d and e). The result clearly illustrated that
the combination of b-hemolysin immunization and passive
neutralization of CAMP factor cooperatively suppressed skin
lesions caused by co-infection of S. aureus and P. acnes.
DISCUSSION
In the human microbiome, the full spectrum of microbial
species residing in humans, P. acnes is ubiquitous in the
general population, whereas S. aureus is present in B25%
(Miller et al., 2007). It has been reported that pathogenic
strains of MRSA bacteria have acquired genes from human
commensal organisms that are present on the skin (Diep
et al., 2006; Grice et al., 2009). Our data demonstrate that
P. acnes enhances the hemolysis of S. aureus (Figure 1),
suggesting that a specific interaction of the bacteria occurs
in the human microbiome (Cogen et al., 2008; Young and
Schmidt, 2008). We identified two secretory toxins—P. acnes
CAMP factor and S. aureus b-hemolysin—that were critically
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Figure 4. Propionibacterium acnes intensifies Staphylococcus aureus-
induced skin lesions. (a) Wild-type S. aureus (SAwt, 1 107 colony-forming
units (CFUs)), P. acnes (PA, 1107CFUs), or P. acnes plus wild-type
S. aureus (PAþ SAwt, 1:1 ratio with a total of 2 107CFUs) in 50 ml
phosphate-buffered saline was subcutaneously injected into the dorsal skins
of imprinting control region mice to induce skin lesions. (b) Lesion sizes
were examined and quantified 2 days after injection. Representative
photographs of dorsal skin lesions are shown. Data are means of two
independent experiments (n¼ 8, *Po0.05 by Student’s t-test).
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engaged in the interaction of P. acnes and S. aureus. The
hemolytic capacity is thought to be a virulence factor for
numerous microbial pathogens to degrade tissue, invade host
cells, disseminate themselves, and resist the host immune
system. Thus, evidence of the enhancement of hemolysis of
S. aureus by P. acnes raises the possibility that S. aureus benefits
from P. acnes present on the skin to invade its human host.
Staphylococcal hemolysins are recognized as chief
virulence factors that contribute to bacterial invasion and
escape from the host immune response (Dinges et al., 2000).
The b-hemolysin, also called sphingomyelinase, is highly
active against sheep and bovine erythrocytes (Larsen et al.,
2002). We observed an augmentation of hemolysis and
cytolysis when cells were treated with both S. aureus
b-hemolysin and P. acnes CAMP factor (Figure 3a and c),
suggesting that S. aureus b-hemolysin may commandeer
P. acnes CAMP factor to enhance the production of host
ceramide for spreading infection in a cell-to-cell manner.
It has been documented that skin and soft tissue infections
make up most of the cases of MRSA infections (Miller et al.,
2005), although community-associated MRSA infections may
cause more severe necrotizing pneumonia (Hageman et al.,
2006) and bacteremia (Seybold et al., 2006). Skin can be the
first place through which the S. aureus/MRSA bacterium
enters a human host. Our data illustrated that P. acnes
enhanced the S. aureus–induced skin lesions (Figure 4). Why
passive neutralization of P. acnes CAMP factor significantly
attenuated the skin lesions caused by the coinfection of
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Figure 5. The immunogenicity of b-hemolysin and the combination of b-hemolysin vaccination and Christie, Atkins, Munch-Peterson (CAMP) factor neutralization
confer immune protection against bacteria-induced skin lesions. (a) Recombinant b-hemolysin (arrowheads) was expressed in E. coli BL21 (DE3). Competent
cells transformed with the pEcoli-Nterm 6HN vector-inserted cDNA encoding b-hemolysin were incubated without () or with (þ ) isopropyl-
b-D-thiogalactopyranoside (IPTG) for 4hours and then subjected to 12% SDS-PAGE. Purified b-hemolysin is shown in the right panel. (b) The identity of recombinant
b-hemolysin was analyzed by Nano liquid chromatography linear trap quadrupole tandem mass spectrometry (NanoLC-LTQ MS/MS). Tryptic digests of purified
recombinant b-hemolysin were subjected to NanoLC-LTQ MS/MS. A sequenced internal peptide (NNDVVIFNEAFDNGASDK) of b-hemolysin is presented. The m/z
value of each ‘‘y’’ and ‘‘b’’ ion in collision-induced dissociation spectra is indicated. All sequenced peptides are shown in Supplementary Table S1 online. (c)
Immunogenicity of b-hemolysin was evaluated by western blotting. Imprinting control region mice were intranasally vaccinated with UV-inactivated E. coli BL21
(DE3) overexpressing b-hemolysin or green fluorescence protein (GFP). Anti-antisera were collected 1 week after second vaccination. One microgram of
recombinant b-hemolysin was separated via 12% SDS-PAGE, transferred to an Immobilon-P polyvinylidene difluoride membrane, and reacted with anti-b-hemolysin
(left lane) or anti-GFP antiserum (right lane), in 1:2,000 dilution. (d) The GFP- (upper row) and b-hemolysin-immunized mice (lower row) were used for evaluation of
immune protection. Mice were injected subcutaneously with the mixture of wild-type Staphylococcus aureus and Propionibacterium acnes (1:1 ratio with a total of
2 107 colony-forming units in 50ml phosphate-buffered saline) that were preincubated with 5% (v/v) anti-CAMP factor antiserum (right panel) or anti-GFP antiserum
(left panel) at 251C for 1hour. Lesion sizes were examined 2 days after injection. (e) Skin lesions were measured and statistics compiled. Representative photographs
of dorsal skin lesions are shown. Data are from two independent replicated experiments (***Po0.001; Tukey’s honest significant difference comparing the four
treatments, in a two-way analysis of variance on log-transformed data comparing the four treatments, with day included as a blocking factor).
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S. aureus and P. acnes (Figure 5d and e) has two possible
explanations. First, antiserum to P. acnes CAMP factor may
exhibit cross-reactivity to S. aureus, leading to a decrease in
skin lesions caused by S. aureus. Second, P. acnes CAMP
factor may be massively secreted while S. aureus is present
and thus exacerbate existing lesions. Our data (Supplemen-
tary Figure S3 online) suggest that anti-CAMP factor
antiserum did not affect the skin lesions induced by S. aureus
alone. However, we cannot rule out the second possibility
that S. aureus stimulates secretion of P. acnes CAMP factor.
Given that recombinant CAMP factor can potentiate the
hemolytic activity of S. aureus (Figure 2a), it is possible that
P. acnes does not need to be alive to exert this cohemolytic
effect. Mixing killed P. acnes with S. aureus in future studies
will determine whether CAMP factor secretion is necessary
to enhance the virulence of S. aureus. Direct measurement of
b-hemolysin and CAMP factor produced by these bacteria
would be useful to determine whether an increase in the
production and/or activities of virulence factors leads to the
augmentation of cytolysis. In fact, it is worthwhile to clarify a
signaling relationship among S. aureus b-hemolysin, P. acnes
CAMP factor, and host ceramide. We have shown that
humoral immunity against P. acnes CAMP factor can mitigate
the in vitro hemolytic activity of S. aureus cocultured
with P. acnes. Although we have shown protection against
S. aureus infected mice through vaccination against
b-hemolysin, we do not have enough evidence to conclude
whether this is a T or B cell mediated immune response.
Adoptive transfer experiments with sera and/or T cells are
crucial to understanding the underlying mechanisms.
Although the overgrowth of P. acnes can cause many
human diseases such as acne vulgaris and toxic shock
syndrome (Yang et al., 2009), the bacterium is a major
commensal in humans (Grice et al., 2009). Unlike active
immunization, passive immunotherapy with local attenuation
of CAMP factor will be less disruptive to P. acnes in distant
locales. The genome of P. acnes has five homologs of the
cohemolytic CAMP factor of S. agalactiae (Jurgens et al.,
1987; Lang and Palmer, 2003; Valanne et al., 2005). Here,
we have shown that neutralization of one (accession number
AY726656) of the CAMP factors in P. acnes dramatically
suppressed the coinfection-induced skin lesions (Figure 5d
and e). Currently, we are determining whether other CAMP
factors can also intensify the b-hemolysin toxicity and if they
can be neutralized by their respective antisera. In conclusion,
we have shown the potential benefit of targeting P. acnes
CAMP factor for S. aureus infections using an animal model.
Although disarming bacteria via neutralization of their secre-
tory toxins may enhance the clearance of bacteria by immune
cells, the immune-mediated blockade of CAMP factor and/or
b-hemolysin in combination with small-molecule inhibitors
directly targeting bacterial particles may be of value for
complete eradication of bacterial infection.
Overall, the study provides the clinical relevance that
passive administration of anti-CAMP factor antibody into
S. aureus b-hemolysin-immunized patients may (i) prevent
systemic bacterial invasion after local colonization at the
initial site of infection; (ii) faciliate the host immune system’s
eradication of disarmed/avirulent bacteria before antibody
reaches the infected site; and (iii) instantly rescue the
inefficiency of vaccines that provoke low titer of antibody
in immunocompromised people or vaccines that have no
activity against new strains of S. aureus/MRSA.
MATERIALS AND METHODS
Bacterial culture
P. acnes (ATCC 6919; Manassas, VA) was cultured on Brucella broth
agar (BD, Sparks, MD) as described previously (Nakatsuji et al.,
2009). Single colonies were inoculated in reinforced Clostridium
medium(Oxford, Hampshire, UK) and cultured at 37 1C under
anaerobic conditions using Gas-Pak (BD Biosciences, San Jose, CA).
S. aureus 113 (ATCC 35556) and S. epidermidis (ATCC 12228)
bacteria were from ATCC. A b-hemolysin-deficient S. aureus strain
and its wild type (National Collection of Type Cultures 8325-4) were
obtained from Pyong Park (Division of Respiratory Diseases,
Children’s Hospital, Harvard Medical School, Boston, MA). An
a-hemolysin-deficient S. aureus strain was obtained from Bill
Schwan (Department of Microbiology, University of Wisconsin–La
Crosse, La Cross, WI). S. aureus and S. epidermidis were cultured on
3% tryptic soy broth (Sigma-Aldrich, St Louis, MO) agar overnight at
37 1C. Bacteria were suspended in an appropriate amount of
phosphate-buffered saline (PBS) for the further experiments.
Hemolytic activity of S. aureus enhanced by P. acnes or CAMP
factor
Sheep blood agar plates were used to determine the cohemolytic
activity of P. acnes or CAMP factor. P. acnes (2 107CFUs),
S. aureus 113 (2 107CFUs), the mixture of P. acnes and S. aureus
113 (1:1 ratio with a total of 2 107CFUs), S. epidermidis
(2 107CFUs), and the mixture of S. epidermidis and S. aureus 113
(1:1 ratio with a total of 2 107CFUs) were all suspended in 10ml PBS
and then streaked on sheep blood agar plates and incubated for 2 days
under anaerobic conditions at 37 1C. For determination of cohemo-
lytic activity of CAMP factor, S. aureus 113 (10ml, 2 107CFUs in
PBS) was streaked on the sheep blood agar plate. A total of 10mg of
recombinant CAMP factor or GFP within 5ml PBS was spotted beside
the S. aureus streak grown at 371C for 18hours.
Molecular cloning, expression, and purification of b-hemolysin
and CAMP factor
The bacterial genomic DNA was prepared as described previously
(Sohail, 1998). For purposes of constructing a plasmid carrying the
hlb gene encoding the b-hemolysin (accession number: X61716), the
gene was amplified by PCR from wild-type S. aureus genomic DNA
as a template, using oligonucleotide primers of forward primer,
50-AAGTCGACATGGTGAAAAAAACAAAATCC-30 (SalI restriction
site is underlined), and reverse primer, 50-ATAAGCTTCTATTTACT
ATAGGCTTTGATTGGG-30 (HindIII restriction site is underlined).
The oligonucleotide primers specific for the hlb gene were also used
for PCR analysis of genomic DNA of various strains of S. aureus.
The CAMP factor (accession number: AY726656) was cloned
from P. acnes genomic DNA, using oligonucleotide primers of
forward primer, 50-ATGTCGACGTCGAGCCGACGACGACCATC
TCG-30 (SalI restriction site is underlined), and reverse primer, 50-AT
AAGCTTGGCAGCCTTCTTGACATCGGGGGAG-30 (HindIII restric-
tion site is underlined). The amplified PCR products and the In-Fusion
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Ready pEcoli-Nterm 6HN expression plasmid (Clontech, Mountain
View, CA) were digested with SalI/HindIII and purified by agarose gel
electrophoresis for ligation. The constructed plasmids were trans-
formed and expressed in E. coli BL21 (DE3) (Invitrogen, Carlsbad, CA).
A pEcoli-Nterm-GFP plasmid (Clontech) was used to express the GFP.
A 2ml overnight culture of E. coli BL21 (DE3) containing expression
plasmids of b-hemolysin, CAMP factor, or GFP, was inoculated into
200ml Luria-Bertani and incubated with isopropyl-b-D-thiogalactopyr-
anoside (1mM; Sigma-Aldrich) for 4 hours. A column with 2ml
Ni-NTA agarose (Qiagen, Valencia, CA) was used for protein
expression and refolding. The purified and refolded protein was
dialyzed overnight at 4 1C against 5 liters of 1 PBS by using Spectra/
Por molecular-porous membrane tubing (molecular weight cutoff:
3,500; Spectrum Laboratories, Rancho Dominguez, CA).
Protein identification via mass spectrometry
In-gel digestion with trypsin and protein identification via a Nano liquid
chromatography linear trap quadrupole tandem mass spectrometry
analysis were performed as described previously (Martin and Clynes,
1993; Shi et al., 2007). SEQUEST was searched with a fragment ion
mass tolerance of 0.5Da and a parent ion tolerance of 1.0Da.
Vaccination and detection of antibodies to b-hemolysin and
CAMP factor
Female ICR mice (Harlan, Indianapolis, IN) B2 months old were
used for vaccination. The mice were intranasally vaccinated with
E. coli BL21 (DE3) overexpressing b-hemolysin, CAMP factor, or
GFP (as the control), which were inactivated by UV (3,500 Jm2)
irradiation. The inactivation of irradiated E. coli BL21 (DE3) was
indicated by its inability to grow on a Luria-Bertani agar plate
(data not shown). For intranasal vaccination, 25 ml of irradiated
(1 109CFUs) E. coli BL21 (DE3) overexpressing b-hemolysin,
CAMP factor, or GFP was pipetted into the nasal cavities of mice.
ICR mice were vaccinated at 3-week intervals for 9 weeks. One
week after the third boost, antisera against b-hemolysin or CAMP
factor were collected individually for western blot analysis using a
goat anti-mouse IgG (Hþ L) conjugated to horseradish peroxidase
(Promega, Madison, WI) and the ECL Western Blotting Substrate
(Pierce, Rockford, IL) for the detection of chemiluminescence.
Proinflammatory MIP-2 detection
The proinflammatory MIP-2 cytokine was determined by sandwich
ELISA using a Quantikine M mouse MIP-2 set (R&D Systems,
Minneapolis, MN).
Skin infection of S. aureus
The wild-type S. aureus (1 107CFUs), P. acnes (1 107CFUs), and
P. acnes plus wild-type S. aureus (1:1 ratio with a total of
2 107CFUs) were suspended in 50ml PBS and subsequently
injected subcutaneously into dorsal skin of the flank of 8- to 12-
week-old female ICR mice, respectively. After injection for 2 days,
the lesion sizes were examined and quantified by using ImageJ
software (National Institutes of Health, Bethesda, MD).
Protective effect of a b-hemolysin-based vaccine along with
CAMP factor neutralization
P. acnes (1 107CFUs in 25ml PBS) was preincubated with 5% (v/v)
anti-CAMP factor or anti-GFP antiserum (as the control) at 251C for
1hour and then mixed with wild-type S. aureus (1 107CFUs in 25ml
PBS). Subsequently, the mixtures were subcutaneously injected into the
dorsal skin of ICR mice that were vaccinated with irradiated E. coli BL21
(DE3) overexpressing b-hemolysin or GFP, respectively. After injection
for 2 days, the lesions were measured using ImageJ software.
Hemolysis assay
The defibrinated sheep blood cells (Lampire Biological Laboratories,
Pipersville, PA) were incubated with individual bacteria (P. acnes or
S. aureus; 2 107CFUs) or a bacterial coculture (P. acnes with various
strains of S. aureus; 2 107CFUs) suspended in 10ml PBS for 2 days.
Incubation of blood cells with Triton X-100 (2%; Sigma-Aldrich) served as
a positive control. The samples were then centrifuged at 800g for
10minutes. The absorbance of hemoglobin release was measured at
540nm and is expressed as percentage of Triton X-100–induced hemo-
lysis. Results given represent mean values from triplicate measurements.
Cell culture and in vitro cytotoxicity assay
A murine macrophage cell line, RAW264.7, was cultured in RPMI
1640 medium, supplemented with 10% heat-inactivated fetal bovine
serum at 371C. Cells (1 105) were infected with 1 106CFUs
(multiplicity of infection¼ 1:10) bacteria. For in vitro neutralization,
complements in sera were deactivated by heating at 561C for
30minutes before adding into bacterial culture. The mixed bacterial
culture media of P. acnes and S. aureus were preincubated in the
presence of 5% (v/v) anti-GFP (as a negative control) or anti-CAMP
factor antiserum at 251C for 1 hour before treatment. Each well of
cells was cocultured with bacterial culture media in 5 ml at 37 1C for
24 hours. Cell viability was determined by an acid phosphatase assay
as described previously (Nakatsuji et al., 2009).
Statistical analysis
Data are presented as mean±SE. Data are represented as means for
measurement of lesion sizes. The Student t-test with criterion Po0.05
was used to determine statistical significance for all experiments. A two-
way analysis of variance model was built to compare the treatment
groups on the basis of log-transformed data with adjustment for the day
of experiments (two independent replicates) shown in Figure 5e. A
Tukey’s honest significant difference test (Miller, 1981) was performed for
pairwise comparisons of the treatment groups at a family-wise error rate
of 5%; the corresponding adjusted P-values were provided.
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